Leen Kawas, Athira
Seattle-based Athira, aiming for tough Alzheimer's and Parkinson's targets, raises $204M for IPO
Following an $85 million Series B round back in June, Athira Pharma is set to become the third biotech in the last three days to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
